| Hu, Shuiying |
Ohio State University
United States |
Prevention of paclitaxel-induced peripheral neuropathy with nilotinib |
5R01CA238946-05 |
|
Rachel Altshuler, Ph.D. |
| Cheville, Andrea Lynne |
Mayo Clinic Rochester
United States |
Achieving Equity through SocioCulturally-informed, Digitally-Enabled Cancer Pain managemeNT” (ASCENT) Clinical Trial |
4R33CA278594-02 |
|
Brennan Streck, Ph.D., R.N., M.P.H. |
| Hu, Shuiying |
Ohio State University
United States |
Prevention of paclitaxel-induced peripheral neuropathy with nilotinib |
5R01CA238946-05 |
|
Rachel Altshuler, Ph.D. |
| Lee, Jeffrey Kuang Zou |
Kaiser Foundation Research Institute
United States |
Multi-Ethnic Multi-Cancer Early Detection and Screening (MED SCREEN) Study |
1UG1CA287011-01 |
|
Elyse LeeVan, M.D., M.P.H. |
| Kelleher, Sarah |
Duke University
United States |
Initial Testing of a Mobile App Pain Coping Intervention for Outpatient Oncology Settings |
5R21CA273832-02 |
|
Brennan Streck, Ph.D., R.N., M.P.H. |
| Brown, Austin L |
Baylor College Of Medicine
United States |
A Systems Epidemiology Approach for Predicting Methotrexate Neurotoxicity in Pediatric Acute Leukemia |
5R01CA272981-02 |
|
Rachel Altshuler, Ph.D. |
| Chibwesha, Carla J |
Univ Of North Carolina Chapel Hill
United States |
Acceptability and feasibility of combination treatment for cervical precancer among South Africa women living with HIV |
5R01CA250850-04 |
|
|
| Chan, Daniel Wanyui |
Johns Hopkins University
United States |
Development of a panel of multiplex biomarkers for the early detection of pancreatic ductal adenocarcinoma and high-risk lesions |
1U01CA274514-01A1 |
PAR-21-334 (U01 Clinical Trial Optional) |
|
| Alambeigi, Farshid |
University Of Texas At Austin
United States |
A Novel Framework for Sensitive and Reliable Early Diagnosis, Topographic Mapping, and Stiffness Classification of Colorectal Cancer Polyps |
1R21CA280747-01A1 |
|
Matthew Young, Ph.D. |
| Salami, Simpa Samuel |
University Of Michigan At Ann Arbor
United States |
Defining the Biological Arc of Grade Group 1 Prostate Cancer |
1R37CA283857-01 |
|
Guillermo Marquez, Ph.D. |